Watson reaches patent settlement for Actos generic
MORRISTOWN, N.J. Watson Pharmaceuticals and Takeda Pharmaceuticals North America have settled a patent litigation case concerning a diabetes drug, Watson announced Wednesday.
The generic drug maker said Takeda granted it a non-exclusive, royalty-free license to its patents covering Actos (pioglitazone hydrochloride), an oral treatment for Type 2 diabetes, in the 15-mg, 30-mg and 45-mg strengths.
Under the agreement, Watson will be allowed to launch its generic Actos in August 2012. The patents covering the drug expire in 2016, according to the Food and Drug Administration.
Actos had sales of $3.4 billion in 2009, according to IMS Health.
No comments found
RediClinic offering Latisse consultations
HOUSTON RediClinic, which operates 22 retail health clinics inside select H-E-B stores in the Greater Houston and Austin area, now is offering Latisse, an FDA-approved prescription treatment to grow lashes.
Latisse is a prescription treatment for hypotrichosis used to grow eyelashes. Eyelash hypotrichosis is another name for not having enough eyelashes or eyelashes that are inadequate. The topical solution must be applied each night on the skin of the upper eyelid margins at the base of the eyelashes. Results are gradual and peak after 12 to 16 weeks.
RediClinic is offering Latisse consultations for $69.
Good to know this. Many women would love to consult first before jumping to using Latisse or buy latisse. It is always good to know first if you are okay with anything you are going to take.
Where exactly can I find this clinic? I want to consult in a very prestigious clinic first before I will purchase and use Latisse. Just want to make sure. Shay Arrellin buy latisse
Bristol-Myers Squibb, AstraZeneca announce postmarketing study for Onglyza
WILMINGTON, Del. Two drug makers hope to find out how well a diabetes drug works in treating patients who run the risk of developing cardiovascular diseases in a post-marketing study announced Tuesday.
Bristol-Myers Squibb and AstraZeneca announced the start of a phase 4 study of 12,000 patients with Type 2 diabetes treated with the drug Onglyza (saxagliptin). The placebo-controlled study, called SAVOR-TIMI 53, will take place over a five-year period and follow patients who have a history of previous cardiovascular problems or multiple risk factors for vascular disease, with the goal of determining whether adding Onglyza to their current standard of care will reduce their risk of cardiovascular death, heart attack or stroke.
The Food and Drug Administration approved Onglyza in July 2009.
No comments found